199 related articles for article (PubMed ID: 36688995)
41. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
42. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
Mitwasi N; Feldmann A; Bergmann R; Berndt N; Arndt C; Koristka S; Kegler A; Jureczek J; Hoffmann A; Ehninger A; Cartellieri M; Albert S; Rossig C; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 Dec; 8(65):108584-108603. PubMed ID: 29312553
[TBL] [Abstract][Full Text] [Related]
43. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Arndt C; Feldmann A; Koristka S; Schäfer M; Bergmann R; Mitwasi N; Berndt N; Bachmann D; Kegler A; Schmitz M; Puentes-Cala E; Soto JA; Ehninger G; Pietzsch J; Liolios C; Wunderlich G; Kotzerke J; Kopka K; Bachmann M
Oncoimmunology; 2019; 8(11):1659095. PubMed ID: 31646084
[TBL] [Abstract][Full Text] [Related]
44. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
[TBL] [Abstract][Full Text] [Related]
45. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
[TBL] [Abstract][Full Text] [Related]
46. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
48. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.
Cao YJ; Wang X; Wang Z; Zhao L; Li S; Zhang Z; Wei X; Yun H; Choi SH; Liu Z; Zhao L; Kazane SA
ACS Synth Biol; 2021 May; 10(5):1176-1183. PubMed ID: 33856201
[TBL] [Abstract][Full Text] [Related]
49. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
50. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment.
Loureiro LR; Hoffmann L; Neuber C; Rupp L; Arndt C; Kegler A; Kubeil M; Hagemeyer CE; Stephan H; Schmitz M; Feldmann A; Bachmann M
J Exp Clin Cancer Res; 2023 Dec; 42(1):341. PubMed ID: 38102692
[TBL] [Abstract][Full Text] [Related]
51. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
52. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
53. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
54. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
56. Innate-like NKp30
Correia MP; Stojanovic A; Wels WS; Cerwenka A
Oncoimmunology; 2021; 10(1):1973783. PubMed ID: 35036073
[TBL] [Abstract][Full Text] [Related]
57. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
58. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
59. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer.
Murali Shankar N; Ortiz-Montero P; Kurzyukova A; Rackwitz W; Künzel SR; Wels WS; Tonn T; Knopf F; Eitler J
Front Immunol; 2023; 14():1254821. PubMed ID: 37885894
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
